News Denali slides after ALS drug flunks clinical test Another clinical trial setback disappoints the ALS patient community, this time involving Denali's eIF2B agonist DNL343.
News NeOnc Technologies has another go at a Nasdaq listing US biotech NeOnc Technologies has applied to list on the Nasdaq as it advances a portfolio of drugs to treat diseases affecting the CNS.
News London-listed Poolbeg discussing Hookipa merger The UK's Poolbeg Pharma has disclosed that it is in talks over a possible takeover by Hookipa, an Austrian biotech that is listed on the Nasdaq.
News CARsgen gets a win for CAR-T in solid tumours CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satri-cel has shown efficacy in gastric cancer, setting up a filing in China.
News Regeneron builds in eye disease tech with Oxular takeover Regeneron has bought Oxular, a UK specialist in retinal diseases, in a move that bolsters its already strong position in ophthalmology therapies.
News Neumora laid low by depression trial failure The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price.
R&D Treating the chronic diseases GLP-1s miss, with Laurent Auda... Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
